Table 2.
Organ involvement in the AOSD patients and in the controls according to 18F-fluorodeoxyglucose-PET/MR-CT and 18F-PET/MR alone and the SUV values for each area.
| SUVmin organ/liver | SUVmax organ/liver | SUVmean organ/liver | N of PET/CT or PET/MR with SUV max ratio > = 2.09 | |
|---|---|---|---|---|
| Affected organs according to PET/CT-MR in 18 AOSD patients (total 23 PET) | ||||
| Spleen | 0.8 ± 0.32 | 1.40 ± 0.41 | 1.07 ± 0.34 | 2/23 |
| BM | 0.91 ± 0.29 | 2.3 ± 0.75 | 1.36 ± 0.48 | 11/23 |
| LN | 2.00 ± 1.25 | 4.79 ± 2.87 | 3.15 ± 1.95 | 9/23 * |
| Pharynx | 2.89 ± 1.38 | 6.94 ± 3.61 | 3.80 ± 1.33 | 8/23 |
| BAT | 3.34 ± 2.98 | 8.34 ± 7.42 | 5.01 ± 1.12 | 3/23 |
| SL glands | 1.52 ± 0.88 | 3.65 ± 2.1 | 2.48 ± 1.5 | 9/23 |
| Affected organs according to PET/MR (only) in AOSD patients | ||||
| Spleen | 0.84 ± 0.36 | 1.41 ± 0.45 | 1.1 ± 0.40 | 1/14 |
| BM | 0.93 ± 0.30 | 2.39 ± 0.81 | 1.40 ± 0.51 | 7/14 |
| Affected organs according to PET/MR in 24 controls | ||||
| Spleen | 0.61 ± 0.14 | 1.05 ± 0.23 | 0.81 ± 0.16 | 0/24 |
| BM | 0.53 ± 0.14 | 1.34 ± 0.36 | 0.75 ± 0.20 | 1/24 |
| LN | Na | Na | Na | |
| Pharynx | 1.74 ± 0.46 | 4.31 ± 1.11 | 2.73 ± 0.78 | 4/24 |
| BAT | na | Na | Na | |
| SL glands | 1.21 ± 0.42 | 2.98 ± 1.05 | 1.86 ± 0.62 | 12/24 |
The number of scans with an SUVmax organ-to-liver ratio ≥2.09 (representing high-uptake areas) are listed.
BAT, brown adipose tissue; BM, bone marrow; LN, lymph nodes; SL, sublingual; SUV, standardized uptake value.
*
Lymph nodes were distributed in the abdominal region (five patients), head and neck district (two patients), axillary lymph nodes (one patient), and mediastinum (one patient).